Experience

Axial Therapeutics, Inc.

• United States
• Biotechnology Research
• 1 - 100 Employee

• Senior Vice President

  • Feb 2023 - Present

  Massachusetts, United States

• Vice President, Clinical Development Sciences and Operations

  • Jun 2022 - Feb 2023



Praxis Precision Medicines, Inc.

• United States
• Biotechnology Research
• 1 - 100 Employee

• Vice President, Clinical Development Sciences

  • Jun 2021 - Feb 2022

  Cambridge, Massachusetts, United States Designed, conducted and/or analyzed data on 14 clinical trails - From Phase I (FIH) through Phase 2B in Essential Tremor, Parkinson's Disease and Major Depressive Disorder

• Senior Medical Director

  • May 2018 - Jun 2021



Takeda

• Japan
• Pharmaceutical Manufacturing
• 700 & Above Employee

• CNS Area Physician, Clinical Translational Science, TREC

  • Mar 2017 - May 2018

  Greater Boston Area Facilitate the transition of early stage therapeutic assets from discovery to later stage development, by designing and executing early clinical trials and biomarker studies within TREC (Translational Research and Early Clinical).



Sage Therapeutics

• United States
• Biotechnology Research
• 400 - 500 Employee

• Senior Scientist

  • Jul 2015 - Mar 2017

  Cambridge, MA Responsibilities include: - Design, source, execute and interpret studies with scientific collaborators from the academic, government, and private sectors - predominantly CROs. Studies span drug discovery including DMPK, molecular pharmacology, in vivo pharmacology, translational neuroscience and IND enabling toxicology. Contributed to the nomination of 5 development candidates. - Serve as pharmacology representative to a clinical stage drug development team in Phase I. Lead the… Show more Responsibilities include: - Design, source, execute and interpret studies with scientific collaborators from the academic, government, and private sectors - predominantly CROs. Studies span drug discovery including DMPK, molecular pharmacology, in vivo pharmacology, translational neuroscience and IND enabling toxicology. Contributed to the nomination of 5 development candidates. - Serve as pharmacology representative to a clinical stage drug development team in Phase I. Lead the writing of the pharmacology/efficacy sections of key regulatory submissions for this team. - Lead the coordinated effort to write a strategically important manuscript detailing the translation of an EEG based biomarker.

• Scientist II

  • Mar 2013 - Jul 2015

  Cambridge, MA Biologist/Pharmacologist. Responsibilities: design, source, execute and interpret studies with scientific collaborators from the academic, government, and private sectors. Studies span drug discovery including DMPK, molecular pharmacology, in vivo pharmacology and IND enabling toxicology. Facilitate software development for virtual drug discovery platform. Contributed to the nomination of 2 development candidates. Specifically contributed to: 1.Interpretation and presentation of… Show more Biologist/Pharmacologist. Responsibilities: design, source, execute and interpret studies with scientific collaborators from the academic, government, and private sectors. Studies span drug discovery including DMPK, molecular pharmacology, in vivo pharmacology and IND enabling toxicology. Facilitate software development for virtual drug discovery platform. Contributed to the nomination of 2 development candidates. Specifically contributed to: 1.Interpretation and presentation of complex behavioral, safety and neurophysiological datasets 2.Off-target selectivity testing – binding and functional assays 3.Translational plan/biomarker strategy 4.Selection of disease indication – diligence on biological rational, epidemiology/market opportunity, and clinical trial feasibility Wrote the Phase I clinical trail design synopsis for the briefing package for a PRE-IND meeting with FDA for one of the development candidate. Planning to write the clinical section of the full IND application.

• Business Development Consultant

  • May 2012 - Feb 2013

  215 First Street, Cambridge, MA National Institutes of Health (NIH) and private funding specialist. Multi-mechanism/disease indication grant writer. Wrote 2 NIH grants including an application to the NIH Blueprint for Neuroscience Research that was awarded, with an estimated value of $10 million. http://neuroscienceblueprint.nih.gov/bpdrugs/bpn.htm



Smart Scheduling

• United States
• Hospitals and Health Care

• Co-founder

  • Feb 2012 - Apr 2016

  Cambridge, MA Smart Scheduling (Arsenal Health) was acquired April 2016 by athenhealth. http://newsroom.athenahealth.com/phoenix.zhtml?c=253091&p=irol-newsArticle&ID=2157141 Smart Scheduling developed software that takes the guesswork out of doctor's office scheduling by optimizing the day¹s clinic appointments using machine learning algorithms to predict the likelihood of a patient missing his or her appointment. Identified the business opportunity, assembled team, served as the initial… Show more Smart Scheduling (Arsenal Health) was acquired April 2016 by athenhealth. http://newsroom.athenahealth.com/phoenix.zhtml?c=253091&p=irol-newsArticle&ID=2157141 Smart Scheduling developed software that takes the guesswork out of doctor's office scheduling by optimizing the day¹s clinic appointments using machine learning algorithms to predict the likelihood of a patient missing his or her appointment. Identified the business opportunity, assembled team, served as the initial motivating force behind company launch, contributed to HIT accelerator applications, and helped source investors for early stage financing. Show less



Massachusetts Institute of Technology

• United States
• Higher Education
• 700 & Above Employee

• Postdoctoral Fellow

  • Dec 2008 - May 2012

  MIT - McGovern Institute for Brain Research I studied the regulation of Npas4, an activity regulated transcription factor, and how it contributes to learning and memory. This work was published as an article in Science, on which I am a coauthor. I have also been involved in collaborations with the laboratories of Guoping Feng and Ed Boyden, the latter resulting in a Nature paper in 2010.



Veterans Health Administration

• Research Associate

  • 2011 - 2012

  Collaborated on writing grants to the VA for exploring the role of activity regulated transcription in Alzheimer's disease.



Beth Israel Deaconess Medical Center

• United States
• Hospitals and Health Care
• 700 & Above Employee

• Medical Intern/Neurology Resident

  • Jul 2006 - Oct 2008

  I was involved in inpatient and outpatient diagnosis and treatment of chronically and critically ill patients from the Boston area.



Boston University School of Medicine

• M.D., Ph.D.

  • 1997 - 2006

  I did my dissertation in the Department of Biochemistry in Dr. Konstantin Kandror's lab. I explored the trafficking of synaptic vesicle proteins. I published two first author papers in the Journal of Biological Chemistry and a second author paper in the Journal of Neuroscience.